

AroCell Q4 - Steady operations

Redeye notes a quarter showing continuing sales growth for AroCell with good cost control. We slightly up our sales estimate for 2023e and lower our WACC following a review of Redeye Quality Rating, resulting in upwards changes to our fair value range.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

AroCell Q4 - Steady operations